| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| Aliases | APE; GIV; GRDN; HkRP1; GIRDIN; KIAA1212 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human CCDC88A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CCDC88A抗体的模拟参考文献示例(请注意文献为虚构，仅供格式参考)：
1. **文献名称**: "CCDC88A modulates hepatocellular carcinoma progression via Wnt/β-catenin signaling"
**作者**: Zhang L, et al.
**摘要**: 本研究利用CCDC88A特异性抗体进行Western blot和免疫组化分析，发现CCDC88A在肝癌组织中高表达，并通过激活Wnt/β-catenin通路促进肿瘤侵袭。抗体验证显示其在肝癌细胞系中的特异性结合能力。
2. **文献名称**: "CCDC88A antibody reveals its role in macrophage polarization during fibrosis"
**作者**: Chen Y, et al.
**摘要**: 通过CCDC88A抗体检测小鼠纤维化模型中的蛋白表达，发现CCDC88A促进巨噬细胞向促纤维化表型转化。研究提示其可能成为肝纤维化的治疗靶点。
3. **文献名称**: "CCDC88A interacts with Dvl2 in glioblastoma invasion: Evidence from co-immunoprecipitation"
**作者**: Müller S, et al.
**摘要**: 使用CCDC88A抗体进行免疫共沉淀实验，证实其与Dishevelled-2(Dvl2)的相互作用，调控胶质母细胞瘤细胞的迁移能力，为靶向治疗提供依据。
4. **文献名称**: "CCDC88A antibody validation in autophagy-deficient murine models"
**作者**: Tanaka K, et al.
**摘要**: 本研究系统验证了多种CCDC88A抗体的特异性，发现在自噬缺陷小鼠模型中，CCDC88A蛋白水平显著升高，提示其参与自噬-炎症反馈调控。
---
**提示**：以上为模拟内容，实际文献需通过PubMed、Google Scholar等平台检索关键词(如"CCDC88A antibody validation"或"CCDC88A immunohistochemistry")获取。建议结合最新研究筛选高影响力期刊论文。
The CCDC88A antibody targets the CCDC88A protein (Coiled-Coil Domain-Containing Protein 88A), also known as HkRP1 or GIV, which is encoded by the CCDC88A gene. This protein is a member of the DExD/H-box helicase family and is characterized by its coiled-coil domains, which mediate protein-protein interactions. CCDC88A plays a role in diverse cellular processes, including cell signaling, migration, and polarity, by acting as a scaffold or adaptor in pathways such as Wnt/β-catenin and G protein-coupled receptor signaling. It has been implicated in cancer progression, neurological disorders, and immune regulation due to its involvement in cytoskeletal reorganization and epithelial-mesenchymal transition (EMT).
Antibodies against CCDC88A are widely used in research to study its expression, localization, and function. They are employed in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect protein levels in tissues or cultured cells. Commercial CCDC88A antibodies are typically raised in hosts such as rabbits or mice, with monoclonal and polyclonal variants available. Researchers often validate these antibodies using knockout controls or siRNA-mediated knockdown to ensure specificity, as cross-reactivity with homologous proteins can occur.
Dysregulation of CCDC88A has been observed in cancers (e.g., colorectal, glioblastoma) and fibrotic diseases, making its antibody a tool for biomarker studies and therapeutic target exploration. However, variability in antibody performance across applications highlights the need for careful validation in experimental settings.
×
